Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in <i>BRCA</i> Carrier Ovarian Cancer Correlating With Platinum-Free Interval
2010 · Journal of Clinical Oncology · 984 citations
https://doi.org/10.1200/jco.2009.26.9589
J
Jacques De Grève
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
461
Papers
12.4K
Citations
51
h-index
179
i10-index
Jacques De Grève is an academic researcher from Universitair Ziekenhuis Brussel. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & BRCA gene mutations in cancer & Colorectal Cancer Treatments and Studies. The author has an h-index of 51, co-authored 392 publications.
ORCID: 0000-0002-2389-0742Papers by this author
worksClinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
2012 · Lung Cancer · 277 citations
https://doi.org/10.1016/j.lungcan.2012.01.008
Functional decline in older patients with cancer receiving chemotherapy: A multicenter prospective study
2017 · Journal of Geriatric Oncology · 137 citations
https://doi.org/10.1016/j.jgo.2017.02.010
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
2019 · Annals of Oncology · 112 citations
https://doi.org/10.1093/annonc/mdz061
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma
2015 · Lung Cancer · 88 citations
https://doi.org/10.1016/j.lungcan.2015.01.013
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
2012 · Breast Cancer Research and Treatment · 85 citations
https://doi.org/10.1007/s10549-012-2126-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat